Key facts
- Vivodyne’s last known valuation is $174.0M (May 2025).
- It has raised $79.6M across 1 recorded rounds; the latest was Later Stage VC ($77.7M) in Feb 2025.
- Notable investors include Khosla Ventures, MBX Capital, Lingotto, Fortius Ventures, Bison Ventures — 12 tracked in total.
- Vivodyne has filed 1 Form D with the SEC, most recently Jun 2025 ($77.7M sold to 18 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Vivodyne
Funding rounds
1 roundsAbout Vivodyne
Developer of a platform designed to provide a more accurate and efficient method for preclinical drug testing. The company's platform utilizes lab-grown human organ models, coupled with advanced robotic systems and sophisticated artificial intelligence, enabling pharmaceutical developers to obtain clinically predictive data, ultimately accelerating the creation of safe and more effective therapeutics.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2020
- Employees
- 40
- Website
- vivodyne.com/
- Ownership
- Privately Held (backing)
Vivodyne doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vivodyne shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vivodyne in its N-PORT filings yet. We sweep new filings monthly.